Repligen Exceeds Forecasts, Eyes Aggressive 2026 Growth Strategy

WALTHAM, Mass. – February 24, 2026 – Repligen Corporation (NASDAQ:RGEN) today delivered a powerful statement of financial health and strategic momentum, reporting fourth-quarter and full-year 2025 results that surpassed expectations and issuing ambitious guidance for 2026. The life sciences firm, a key supplier of bioprocessing technologies for manufacturing biological drugs, demonstrated significant growth that outpaced many of its larger industry peers.

The company announced fourth-quarter revenue of $198 million, an 18% increase as reported and a 14% organic increase year-over-year. For the full year 2025, revenue reached $738 million, a 16% increase on both a reported and organic non-COVID basis. This performance exceeded the upper end of its previous financial guidance, signaling strong execution and sustained demand for its products.

Looking ahead, Repligen projected confidence with its full-year 2026 financial guidance, forecasting revenue in the range of $810 million to $840 million. This represents anticipated growth of 10% to 14% and includes an expected 150 basis point expansion in adjusted operating margin, underscoring a dual focus on top-line growth and operational efficiency.

“We had a great finish to 2025 with 14% organic growth in the quarter led by Analytics and Proteins,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “We are thrilled by our strong performance in 2025 with 16% organic non-COVID growth driven by traction across our differentiated portfolio, while continuing to expand margins.”

Strategic Execution Drives Market Outperformance

Repligen's impressive growth figures stand out in the competitive bioprocessing landscape. While larger diversified life sciences companies like Danaher Corporation and Thermo Fisher Scientific reported more modest core revenue growth in the low-to-mid single digits for 2025, Repligen's 14% organic growth highlights the success of its focused strategy. This outperformance suggests that its specialized portfolio in areas like filtration, chromatography, and analytics is resonating deeply with its customer base of biopharmaceutical developers and contract manufacturing organizations (CDMOs).

The company's ability to not only grow revenue but also expand margins is a testament to its operational discipline. For the full year 2025, Repligen increased its adjusted operating margins by 90 basis points. The forecast for a further 150 basis point expansion in 2026 signals management’s confidence in its ability to scale operations efficiently, even as it continues to invest in growth initiatives. This financial strength provides a solid foundation for the company to pursue its strategic priorities, including commercial expansion, operational scaling, and continued innovation.

Innovation as a Buffer to Sector Headwinds

While the overall outlook is strong, Repligen’s guidance acknowledged a specific challenge within the industry: a “two-point gene therapy headwind.” This reflects broader difficulties in the gene therapy sector, which, despite its immense promise, is grappling with significant manufacturing hurdles. These include challenges in scaling production from clinical to commercial volumes, extremely high manufacturing costs, and regulatory complexities that can slow development timelines.

However, Repligen is not just bracing for these headwinds; it is actively developing solutions to address them. In late 2025, the company launched three new high-performance chromatography resins: AVIPure HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA. These products are specifically engineered to tackle purification bottlenecks in the manufacturing of viral vectors, a critical component of many gene therapies. Built on proprietary bead technology, these resins are designed to offer higher binding capacity and faster processing times, directly addressing the industry's need for more efficient and scalable manufacturing solutions.

This focus on targeted innovation demonstrates a key part of Repligen's strategy: turning industry challenges into commercial opportunities. By providing tools that help drug developers improve yields and accelerate timelines, the company solidifies its role as an indispensable partner in the production of next-generation medicines. The expansion of its Analytics portfolio through M&A in 2025 further strengthens this position, providing customers with more advanced tools to monitor and control complex biomanufacturing processes.

Tapping into Asia's Bioprocessing Boom

Beyond product innovation, Repligen is pursuing aggressive geographic expansion to fuel future growth. In the fourth quarter of 2025, the company opened a new office in Singapore and expanded its operational footprint in Japan. This move strategically positions Repligen to capitalize on the booming Asia-Pacific (APAC) biopharmaceutical market.

Industry analysis identifies the APAC region as the fastest-growing bioprocessing market globally, with projections showing a compound annual growth rate (CAGR) exceeding 15% through the end of the decade. This growth is driven by supportive government policies, increasing investment in healthcare infrastructure, and a rising number of biopharmaceutical companies and CDMOs establishing operations in countries like China, India, South Korea, and Singapore.

By establishing a direct commercial and operational presence in these key hubs, Repligen can provide more immediate support to its regional customers, shorten supply chains, and better understand local market needs. This strategic push into Asia is not merely an incremental expansion but a crucial step toward securing long-term growth and diversifying its revenue base in one of the world's most dynamic economic regions.

As the company moves into 2026, its strategy appears clear. “We are investing with intention: expanding our commercial presence and scaling our operations for greater agility,” Loeillot stated. This intentional approach, combining robust financial performance with targeted innovation and strategic global expansion, positions Repligen to continue its trajectory as a leader in the essential, high-growth field of bioprocessing.